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Abstract Cardiovascular disease, including stroke, heart
failure and kidney disease, has been common in sub-Sa-
haran Africa for many years, and rapid urbanization is
causing an upsurge of ischaemic heart disease and meta-
bolic disorders. At least two-thirds of cardiovascular deaths
now occur in low- and middle-income countries, bringing a
double burden of disease to poor and developing world
economies. High blood pressure (or hypertension) is by far
the commonest underlying risk factor for cardiovascular
disease. Its prevention, detection, treatment and control in
sub-Saharan Africa are haphazard and suboptimal. This is
due to a combination of lack of resources and health-care
systems, non-existent effective preventive strategies at a
population level, lack of sustainable drug therapy, and
barriers to complete compliance with prescribed medica-
tions. The economic impact for loss of productive years of
life and the need to divert scarce resources to tertiary care
are substantial.
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Introduction
Despite significant improvement in health research in the
African region since 2000 [1], the quality of information on
the determinants of health and disease and of studies of
implementation of effective preventive and therapeutic
strategies remain scanty. The Global Burden of Disease,
Injuries and Risk Factor Study is the first systematic and
comprehensive attempt to map and quantify risk factors
and diseases to identify emerging threats to population
health and opportunities for prevention [2–5]. Of particular
interest, the analyses of the burden of death and disability
attributable to modifiable risk factors have identified
emerging threats in risk factors traditionally seen in
developed countries, like tobacco smoking, obesity and
high salt intake [2–7]. They explain the surge in the burden
of cardiovascular disease (CVD) in sub-Saharan Africa,
namely hypertension, renal disease, and heart failure. This
upsurge of the CVD epidemic poses an additional burden
on the already over-burdened health-care systems in these
settings creating critical challenges to both national health
systems and policy development that can impede the
development of a strategic plan to address the CVD
epidemic.
The burden of cardiovascular disease
in sub-Saharan Africa
CVD is a major global public health crisis, being responsible
for 30 % of worldwide deaths in 2008 (17 million deaths
worldwide from an annual total of 57 million deaths) with an
alarming 80 % of these deaths occurring in low- and middle-
income countries (LMICs) [8]. Whilst effective measures
are being put in place in high-income countries resulting in a
decline in the rate of CVD [9], CVD mortality is on a steady
rise in LMICs with rates of up to 300–600 deaths attributed
to CVD per 100,000 population, and is projected to increase
causing preventable loss of lives [8]. The uncontrolled CVD
epidemic is associated with increasing socio-economic costs
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with high levels of disability and loss of productivity,
exacerbating poverty and increasing health inequalities. The
poor have the worst outcomes from CVD, largely because of
their inability to access to or afford preventive services and
ongoing treatments. Much of the population risk of CVD is
attributable to nine modifiable traditional risk factors,
including smoking, history of hypertension or diabetes,
obesity, unhealthy diet, lack of physical activity, excessive
alcohol consumption, raised blood lipids and psychosocial
factors [10]. Eight of these risk factors (excessive alcohol
use, tobacco use, high blood pressure, high body mass index
(BMI), high cholesterol, high blood glucose, dietary choices
and physical inactivity) account for 61 % of CVD deaths
globally. About 84 % of the total global burden of disease
they cause occurs in LMICs, with studies showing that
alleviating exposure to these eight risk factors would
improve global life expectancy by almost 5 years [11, 12].
In 2010, the three leading risk factors for global disease
burden were high blood pressure [7.0 % of global disability-
adjusted life-years (DALYs), where a DALY is to be con-
sidered as a year of healthy life lost], tobacco smoking
including second-hand smoke (6.3 %), and household air
pollution from solid fuels (4.3 %) [3]. Dietary risk factors
and physical inactivity collectively accounted for 10.0 % of
global DALYs in 2010, with the most prominent dietary
risks being diets low in fruits and those high in sodium (or
salt) [3]. Thus, further elucidation of the role of these risk
factors is important for developing clear and effective
strategies for improving global health. Notwithstanding the
importance of communicable diseases, child and maternal
health and malnutrition, unsafe water and sanitation, and
malaria as leading causes of loss of DALYs, chronic disease
has seen a rapid increase in sub-Saharan Africa from 1990 to
2010, ranking in the first few places [1]. For example, stroke
mortality rates, measured in both urban and rural Tanzania
by validated verbal autopsies, were higher than those of
England and Wales [13] and of black people in Northern
Manhattan [14] (Fig. 1), suggesting that untreated hyper-
tension is an important factor. Sub-Saharan Africa is expe-
riencing a double burden of disease that calls for a more
integrated approach for the detection, prevention and man-
agement of CVD in LMICs.
Hypertension in sub-Saharan Africa
CVD is the leading cause of death worldwide and hyper-
tension is the leading associated risk factor [2, 3]. High
blood pressure accounts for 9.4 million deaths, more than
elevated BMI, fasting plasma glucose, and total cholesterol
combined [3]. As of 2008, almost 1 billion people had
uncontrolled hypertension worldwide [15]. The African
region has the highest prevalence rate, 46 % of adults aged
25 and above. It has been suggested that the prevalence of
CVD and hypertension are increasing rapidly in sub-Sa-
haran Africa [16]. The current prevalence in many devel-
oping countries, particularly in urban areas, is already as
high as that seen in developed countries [17, 18]. The
number of adults with hypertension in 2025 is predicted to
increase by about 60 % to a total of 1.56 billion [18], with
disproportionate prevalence in developing countries
including sub-Saharan Africa. In contrast with other CVD
risks such as high BMI, the burden of hypertension is
greater in lower income countries than higher income set-
tings [19]. Multiple risk factors positively interact to
exacerbate CVD risks. Hypertension, for example, com-
bined with unhealthy diets and lack of physical activity
Fig. 1 a Number and yearly rate (per 100,000) of deaths from stroke
in 10-year age-bands in adult men and women in Dar-es-Salaam, Hai
district, Morogoro rural district, and England and Wales (1992) (from
Walker et al. [13]). b Age-specific stroke rates for people aged
45 years or over in Hai, Dar-es-Salaam, and black people in Northern
Manhattan (from Walker et al. [14])
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(sodium and alcohol consumption, high BMI, and low
physical activity), has a multiplicative negative effect on
CVD mortality and DALYs [3]. A substantial part of the
CVD risk of death and DALYs attributable to these factors
is not only exacerbated by, but also mediated through high
blood pressure [3]. In LMICs, overweight or obesity are
associated with high blood pressure or with progression to
hypertension [20, 21]. Hypertension is also a determinant
of chronic kidney disease (CKD), a recognized marker of
the poor health outcomes of hypertension and diabetes
[22]. Moreover, growing evidence indicates that CKD is a
strong cardiovascular risk factor in itself [23]. In sub-Sa-
haran Africa cardiovascular and renal disease are important
contributors to morbidity and mortality (up to a quarter),
both among acute medical admissions and among outpa-
tient hypertensives, in whom renal disease is an important
complication [24].
In sub-Saharan Africa, the prevention, detection, man-
agement and control of hypertension should now be
regarded as a high priority [25]. It is estimated that if the
10–20 million people who are believed to have hyperten-
sion in sub-Saharan Africa were treated effectively, about
250,000 deaths would be prevented annually [25]. Sadly,
repeated reports over the years indicate that although the
prevalence of hypertension has reached—and in some parts
of Africa overcome—that seen in the developed world, the
prevention, detection, management and control of high
blood pressure are haphazard and insufficient [26, 27]. In a
large community-based survey of adults in rural and semi-
urban Ghana, the prevalence of hypertension is 28.7 %
overall, comparable in men and women, but higher in semi-
urban compared to rural villages (32.9 versus 24.1 %), and
it increases with age [28]. Detection rate is low, lower in
men than women (13.9 versus 27.3 %) (Fig. 2). Treatment
and control rates are low in both groups (7.8 and 4.4 versus
13.6 and 1.7 %). Detection, treatment, and control rates are
higher in semi-urban (25.7, 14.3, and 3.4 %) than in rural
villages (16.4, 6.9, and 1.7 %). The data confirm that
hypertension is common in adults in Ghana, particularly in
areas of rapid urbanization. Detection rates are suboptimal
in both men and women, especially in rural areas. Ade-
quate treatment of high blood pressure is at a very low level
[28].
Reduction in salt consumption in sub-Saharan
Africa
In Africa, the reduction in population attributable risk when
blood pressure is lowered is 13 times greater than in the
USA [25]. However, in places where there is poor health-
care provision, the detection of hypertension is still hap-
hazard and unreliable, and population-wide strategies to
reduce blood pressure might have an important impact on
the number of cardiovascular events—especially strokes,
kidney disease and heart failure—in the community. There
is good evidence that a reduction in salt intake reduces
blood pressure [29], and that black people are more sen-
sitive than white people to the beneficial effect of reducing
salt intake [30]. The Global Burden of Disease Study on
Salt [7] estimates that 1.65 million deaths from cardio-
vascular causes that occurred in 2010 are to be attributed to
salt consumption above a reference level of 2.0 g of
sodium (equivalent to 5 g of salt) per day, and that they
could have been averted by a moderate population reduc-
tion in salt consumption. In the western world, notwith-
standing this good evidence, it has been difficult to
implement successful salt reduction strategies in the pop-
ulation, since most of the salt ingested is in processed food
[30, 31]. So, any intervention would involve the partici-
pation of the food industry [31]. In contrast, in populations
whose intake of processed food is negligible—such as in
semi-urban and rural sub-Saharan Africa [32]—salt
reduction strategies based on health promotion, increased
Fig. 2 Top proportion of people with hypertension, who were
detected, treated, and controlled (i.e., BP 140 and 90 mmHg) by
gender and age group in Ashanti, West Africa. Hypertension is
defined as systolic BP 140 and/or diastolic BP 90 mmHg, or on anti-
hypertensive medication. Bottom proportion of people with hyper-
tension, as defined above, who were detected, treated, and controlled
(i.e., BP 140 and 90 mmHg) in rural and semi-urban villages by age
group (from Cappuccio et al. [28])
Intern Emerg Med (2016) 11:299–305 301
123
awareness and behavioural changes in individuals and
groups ought to be relatively easy to implement, and have a
good chance of success [33]. Two trials in sub-Saharan
Africa have confirmed that simple, cost-effective, and
culturally adapted behavioural and educational interven-
tions to reduce blood pressure with dietary salt reduction
can be successfully implemented [33–35]. In the study in
south west Nigeria 82 normotensive adults participants (49
men and 33 women) received dietary advice to reduce
sodium intake and to maintain it for 2 weeks. Both blood
pressure and 24 h urinary sodium excretion (a marker of
intake) were measured before and after the intervention.
Salt intake fell by approximately 4.6 g per day and systolic
blood pressure by 4.7 mmHg in men and 7.0 mmHg in
women [34]. In a similar pilot study in rural Ghana, 20
adult normotensive farmers (8 men and 12 women) par-
ticipated in a salt reduction trial of 4-week duration [33].
Both blood pressure and 24 h urinary sodium excretion
were measured at baseline and 4 weeks after attending a
daily 1.5 h session of vigorous nutrition education for a
week, followed by weekly sessions thereafter. At the end of
the study there was a fall in salt consumption of about
50 % (approx. 2.9 g per day) despite the initial low salt
consumption (average 5.8 g per day). At the same time
blood pressure fell by 6.4/4.5 mmHg (Fig. 3). Finally, in a
much larger and longer-term community-based cluster
randomized trial of moderate reduction in salt consumption
through health promotion in twelve rural and semi-urban
villages in the Ashanti region of Ghana, over 1000 adult
men and women took part in a 6-month intervention aiming
at reducing the population blood pressure through health
education on the detrimental effects of high salt con-
sumption [35]. Blood pressure was measured at baseline, 3
and 6 months after the intervention took place. The inter-
vention consisted of an intensive health education pro-
gramme delivered by community health workers to
villagers, daily for the first week of the study, and once
weekly thereafter. The sessions were held in communal
areas like churches, churchyards, schools and community
centres. Salt intake was monitored by repeated 24 h urine
collections throughout. After 6 months the intervention
resulted in a fall in blood pressure of 2.5/3.9 mmHg. There
was a fall in average population systolic blood pressure of
1.3 mmHg for just under 3 g of salt reduction. The
impending epidemic of cardiovascular disease in sub-Sa-
haran Africa in a context of lack of resources is a serious
global public health challenge. Community-based strate-
gies of health promotion for the management of chronic
disease through lifestyle change in sub-Saharan Africa
should be considered. Priority should be given to the cost-
effective population salt reduction strategy, a global pri-
ority to reduce the burden of cardiovascular disease by
25 % by 2025 [30].
Drug therapy in sub-Saharan Africa
There is sufficient evidence to suggest that the patho-
physiology of hypertension varies by ethnic groups, so that
the hypertension seen in people of African descent, whe-
ther living in Africa or migrated through the different
diasporas, shows distinct features in terms of presentations,
underlying mechanisms, response to treatments (pharma-
cological and not) and susceptibility to target organ dam-
age and complications [36–38]. Hypertension in Africa is
characterized, by and large, by low-renin levels [37]. The
blunted response of the renin-angiotensin-aldosterone sys-
tem to a variety of physiological stimulations makes the
blood pressure response of people of African origin more
sensitive to changes in salt intake (excessive raises for
increases in salt intake and significant falls for reductions),
and less responsive to drugs that reduce blood pressure by
acting on inhibitions of pathways of the renin-angiotensin-
aldosterone system [37]. In general, African patients do not
respond as well as other groups to monotherapies with
blockers of renin production (like beta-blockers) or drugs
Fig. 3 Effects of a 4-week intervention aiming at reducing dietary
salt consumption in 20 adult farmers in the Ashanti region of Ghana
(from Cappuccio et al. [33])
302 Intern Emerg Med (2016) 11:299–305
123
that block either the production (ACE-inhibitors) or the
action (angiotensin-receptor blockers) of angiotensin II
[39]. In ALLHAT, a randomized controlled clinical trial of
different classes of anti-hypertensives used as monother-
apy, black patients treated with ACE-inhibitors show the
least blood pressure response and a blunted benefit on
stroke incidence [40]. These shortcomings, however, are
overcome once hypertension is treated in combination
therapy [37]. So, for the management of hypertension in
Africa, initiation treatment regimens based on diuretics and
calcium-channel blockers should be the first choice.
Compliance with treatment is a particular issue for
patients with chronic disease and for clinical staff, and
more so in LMICs with scarce health-care facilities. Since
it is difficult to sustain motivation for treatment, especially
for asymptomatic conditions, how can patients with
chronic conditions be helped to comply with treatment?
Methods include identifying side effects, educating patients
in the need for long-term management, simplifying treat-
ment and involving the patient in agreeing to an accept-
able drug regimen: these strategies are shown to improve
compliance. Obviously, blood pressure control requires
compliance with prescribed medications.
In sub-Saharan Africa the unaffordable cost of sustain-
ing chronic management is the commonest cause of non-
compliance with prescribed regimes and lack of blood
pressure control [41]. However, forgetfulness and prejudice
of untoward effects also play a role [42]. In addition to lack
of affordability, likely predictors of non-compliance are
level of educational attainment, and the tendency to seek
alternative treatment through traditional medicine [42],
suggesting a sceptical approach to the benefits of the
conventional health-care provided by hospitals and clinics.
The only available method of measuring compliance at
clinics in resource-poor areas is patient-reported treatment
taking, although this may result in over-estimation.
Reporting by patient is a low-technology approach that
reinforces health education by emphasizing the contribu-
tion of patients and health-care professionals in establish-
ing treatment.
Conclusions
In 2005 global health funding per death for HIV/AIDS was
$1029 compared with $320 for non-communicable diseases
[43], indicating that there is a widespread apathy with
major health development funds, placing less emphasis in
tackling non-communicable diseases in LMICs compared
to other diseases. Thus, concerted global, regional and local
partnerships are pivotal to address this silent epidemic. The
United Nations General Assembly convened a high-level
meeting on non-communicable diseases in New York in
September 2011 to take action against this global epidemic
[30]. As a result the World Health Organization was tasked
with delivering a compelling agenda, now enshrined in the
WHO Global Action Plan for the prevention and control of
non-communicable diseases covering the period
2013–2020. National governments, policy-makers and
international development partners have a key role in
ensuring that CVD prevention and control become a major
part of the health-care development agenda.
CVD creates an enormous impact on socio-economic
development due to societal and global determinants [43,
44] as many of those in the high-risk group are at the peak
of their productive and economic activity [45, 46]. These
determinants include rapid globalization, unplanned
urbanization, global trade and agricultural policies amongst
other things, which ultimately influence an individual’s or a
society’s ability to make healthy choices contributing to its
negative impact on social and economic growth in LMICs
[47]. The economic impact for loss of productive years of
life and the need to divert scarce resources to tertiary care
are substantial.
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